NIH begins clinical trial testing COVID-19 vaccine in pregnant women
- S&P 500 falls from record high as job growth slows
- Private Sector Employment Increased by 330,000 Jobs in July, Missing Expectations
- General Motors (GM) Misses on Profit Estimates as Bolt EV Recall Weighs on Earnings, Challenging Chip Situation and 'Cautious' Profit Outlook Pulling Shares Lower Says Analyst
- U.S. services sector index races to record high in July -ISM survey
- Softbank-Backed Zymergen (ZY) Crashes Over 70% as CEO Departs, Product Revenue Not Possible in 2021 and 'Immaterial' in 2022, At Least 6 Firms Downgrade
FILE PHOTO: A woman receives a COVID-19 vaccine at a clinic in Philadelphia, Pennsylvania, U.S., May 18, 2021. REUTERS/Hannah Beier/File Photo
News and research before you hear about it on CNBC and others. Claim your 1-week free trial to StreetInsider Premium here.
By Dania Nadeem
(Reuters) - The U.S. National Institutes of Health (NIH) said on Wednesday it had begun a study to evaluate the immune responses generated by COVID-19 vaccines in pregnant or postpartum women.
Pregnant women are at higher risk of complications including premature birth, high blood pressure with organ failure risk, need for intensive care and possible death, according to the NIH.
A research study conducted in February in Israel showed that antibodies were detected in all 20 women administered with both the doses of the Pfizer/BioNTech vaccine during their third trimester of pregnancy and also in their newborns.
Pfizer and BioNTech in February started a separate trial, with 4,000 international volunteers, evaluating safety and effectiveness of their COVID-19 vaccine in healthy pregnant women.
The NIH study, MOMI-VAX, will measure the development and durability of antibodies against the coronavirus in women vaccinated during pregnancy or the first two postpartum months.
The researchers will assess vaccine safety and also evaluate whether vaccinated pregnant women pass along protection to their babies via the placenta or breast milk.
Many pregnant women in the United States have already received the COVID-19 vaccine available under emergency use authorization.
"The results of this study will fill gaps in our knowledge and help inform policy recommendations and personal decision-making on COVID-19 vaccination during pregnancy," National Institute of Allergy and Infectious Diseases Director (NIAID) Dr Anthony Fauci said. NIAID is financing the study.
The trial will enroll up to 750 pregnant and 250 postpartum women within two months of delivery, who have already received or will receive a COVID-19 vaccine authorized by the U.S. Food and Drug Administration (FDA).
The FDA has authorized vaccines from Moderna, Pfizer-BioNTech and Johnson & Johnson for emergency use.
(Reporting by Dania Nadeem in Bengaluru)
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- China outlook positive despite recent regulatory changes - AIA
- Rolls-Royce plans to sell ITP Aero to Bain and Sener for $1.9 billion - report
- Biden says U.S. will send $100 million more in aid to Lebanon
Create E-mail Alert Related CategoriesReuters
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!